Get the Stockscreener App
2.45
1.24%
0.03
Pre-market:
2.45
Gossamer Bio Inc stock is traded at $2.45, with a volume of 2.13M.
It is up +1.24% in the last 24 hours and down -6.84% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
See More
Previous Close:
$2.42
Open:
$2.43
24h Volume:
2.13M
Relative Volume:
0.58
Market Cap:
$557.08M
Revenue:
-
Net Income/Loss:
$-179.82M
P/E Ratio:
-1.8421
EPS:
-1.33
Net Cash Flow:
$-159.16M
1W Performance:
-1.21%
1M Performance:
-6.84%
6M Performance:
+140.20%
1Y Performance:
+179.04%
1-Day Range:
$2.38
$2.52
1-Week Range:
$2.2808
$2.53
52-Week Range:
$0.6617
$3.60
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
2.45 | 553.89M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-25 | Upgrade | UBS | Neutral → Buy |
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Will Gossamer Bio Inc. (4GB) stock keep raising dividendsPortfolio Value Report & Low Drawdown Trading Strategies - newser.com
Will Gossamer Bio Inc. (4GB) stock issue positive guidance2025 Year in Review & Stock Portfolio Risk Control - newser.com
Is Gossamer Bio Inc. stock affected by interest rate hikesJuly 2025 Drop Watch & Free Community Supported Trade Ideas - newser.com
Why millennials buy Gossamer Bio Inc. (4GB) stockQuarterly Profit Review & Real-Time Buy Signal Alerts - newser.com
Is now a turning point for Gossamer Bio Inc.July 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
Why Gossamer Bio Inc. (4GB) stock could outperform next year2025 Investor Takeaways & Weekly Chart Analysis and Guides - newser.com
Ranking Gossamer Bio Inc. among high performing stocks via toolsEarnings Beat & High Accuracy Buy Signal Tips - newser.com
What Wall Street predicts for Gossamer Bio Inc. stock price2025 Volume Leaders & Technical Confirmation Trade Alerts - newser.com
How to use Fibonacci retracement on Gossamer Bio Inc.Product Launch & Weekly High Conviction Ideas - newser.com
Can momentum traders help lift Gossamer Bio Inc.Rate Cut & High Conviction Buy Zone Alerts - newser.com
What Fibonacci levels say about Gossamer Bio Inc. rebound2025 Price Momentum & High Return Stock Watch Alerts - newser.com
Is Gossamer Bio Inc. (4GB) stock nearing a technical breakout2025 Risk Factors & Expert Approved Trade Ideas - newser.com
Institutional Investors Control 62% of Gossamer Bio, Inc. (NASDAQ:GOSS) and Were Rewarded Last Week After Stock Increased 16% - 富途牛牛
Published on: 2025-10-31 05:26:53 - newser.com
Gossamer Bio (GOSS) to Release Quarterly Earnings on Thursday - MarketBeat
Does Gossamer Bio Inc. show high probability of reboundOptions Play & Free Community Supported Trade Ideas - newser.com
Using portfolio simulators with Gossamer Bio Inc. includedWeekly Loss Report & Free Fast Gain Swing Trade Alerts - newser.com
Why Gossamer Bio Inc. stock remains undervaluedJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com
Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Will Gossamer Bio Inc. stock recover faster than marketForecast Cut & Long-Term Growth Plans - newser.com
Is Gossamer Bio Inc. (4GB) stock supported by strong fundamentalsWeekly Loss Report & Fast Exit and Entry Trade Guides - newser.com
Analyzing net buyer seller activity in Gossamer Bio Inc.Weekly Trend Summary & Safe Entry Trade Signal Reports - newser.com
Published on: 2025-10-29 05:37:17 - newser.com
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):